# COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients

> **NCT04498286** · — · COMPLETED · sponsor: **Zoé van Kempen** · enrollment: 546 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DIAGNOSTIC_TEST:** Testing of SARS-CoV-2 antibodies

## Key facts

- **NCT ID:** NCT04498286
- **Lead sponsor:** Zoé van Kempen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-08
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 546 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498286, "COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04498286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*